Talk Of $1 Billion Fine On Ranbaxy By U.S. FDA Dents Stock; Analysts Divided Over Exact Penalty
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Shares of Ranbaxy Laboratories Ltd., listed on the Indian stock exchanges, plunged 6% May 5 to 426 Indian Rupees ($9.48) per share, reacting sharply to a Fortune magazine report that claimed the company may be fined over $1 billion as part of a protracted negotiation and settlement process with U.S. FDA
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?
Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.